Long-term treatment with thymomodulin reduces airway hyperresponsiveness to methacholine.
We investigated the effect of thymomodulin, a calf thymus acid lysate with immunomodulating activity, on bronchial hyperresponsiveness to methacholine of atopic subjects with asthma. In 16 subjects we measured airway responsiveness at 30, 60, and 90 days after treatment with placebo (eight subjects) or thymomodulin (eight subjects; 80 mg daily orally). The degree of bronchial responsiveness to methacholine was significantly reduced at 90 days during treatment with thymomodulin and remained reduced, even if not significantly, 60 days after cessation of treatment.
Bagnato
A
A
Servizio di Fisiopatologia Respiratoria, Ospedale di Codroipo, Udine, Italy.
Brovedani
P
P
Comina
P
P
Molinaro
P
P
Scalzo
C
C
Triolo
V A
VA
Milani
G
G
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000150:complications / Q000276:immunology / Q000628:therapy; D001980:Bronchi / Q000503:physiopathology*; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000150:complications / Q000276:immunology; D007167:Immunotherapy; D008297:Male; D008688:Methacholine Compounds / Q000494:pharmacology*; D008875:Middle Aged; D011897:Random Allocation; D013949:Thymus Extracts / Q000627:therapeutic use*
D006634:Histamine H1 Antagonists; D008688:Methacholine Compounds; D013949:Thymus Extracts; C051006:thymomodulin